<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252963</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MUC-401</org_study_id>
    <nct_id>NCT04252963</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)</brief_title>
  <official_title>Double-blind, Randomized, Placebo Controlled, Multicenter, Phase IV Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet (Streptokinase • Streptodornase) in Patients With Acute Upper Respiratory Infection or Acute Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 4 study to evaluate efficacy and safety of MUCOLASE tablet (streptokinase •
      streptodornase)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, placebo controlled, multicenter, phase 4 clinical trial to assess
      the efficacy and safety of MUCOLASE tablet (streptokinase • streptodornase) in patients with
      acute upper respiratory infection or acute bronchitis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in BSS (Bronchitis Severity Score)</measure>
    <time_frame>baseline, 7 days</time_frame>
    <description>BSS (Bronchitis Severity Score) is derived by summing responses to five major symptoms (i. e. cough, sputum, rales/rhonchi, chest pain during coughing, dyspnoea) with higher scores indicating more severe symptomatology, rated from 0 to 4 (0 = absent, 1 = mild, 2=moderate, 3 = severe, 4 = very severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in each symptom score of BSS (Bronchitis Severity Score)</measure>
    <time_frame>baseline, 7 days</time_frame>
    <description>BSS (Bronchitis Severity Score) is derived by summing responses to five major symptoms (i. e. cough, sputum, rales/rhonchi, chest pain during coughing, dyspnoea) with higher scores indicating more severe symptomatology, rated from 0 to 4 (0 = absent, 1 = mild, 2=moderate, 3 = severe, 4 = very severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cough/sputum domain score of BSS (Bronchitis Severity Score)</measure>
    <time_frame>baseline, 7 days</time_frame>
    <description>BSS (Bronchitis Severity Score) is derived by summing responses to five major symptoms (i. e. cough, sputum, rales/rhonchi, chest pain during coughing, dyspnoea) with higher scores indicating more severe symptomatology, rated from 0 to 4 (0 = absent, 1 = mild, 2=moderate, 3 = severe, 4 = very severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resolution rate of each symptom</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of use of relief drugs</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrative Medicine Outcomes Scale</measure>
    <time_frame>7 days</time_frame>
    <description>Integrative Medicine Outcomes Scale is assessed separately by th subjects and thd investigators at end of study, based on BSS of baseline. (Scoring system: 1 = complete recovery, 2 = major improvement, 3 = slight-to-moderate improvement, 4 = no change, 5 =deterioration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrative Medicine Patient Satisfaction Scales</measure>
    <time_frame>7 days</time_frame>
    <description>Integrative Medicine Outcomes Scale is assessed by subgects at end of study. (Scoring system: 1 = very satisfied, 2 = satisfied, 3 = neutral, 4 = dissatisfied, 5 =very dissatisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Acute Upper Respiratory Infection</condition>
  <condition>Acute Bronchitis</condition>
  <arm_group>
    <arm_group_label>Mucolase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MUCOLASE tablet (streptokinase • streptodornase)</intervention_name>
    <description>streptokinase • streptodornase 5mg</description>
    <arm_group_label>Mucolase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of MUCOLASE tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19≤ age

          -  Patients with acute upper respiratory infection or acute bronchitis

          -  Patients with cough and phlegm within 48 hrs as of Visit 1

          -  Patients understood the consents and purpose of this trial and signed consent form

        Exclusion Criteria:

          -  Patients with high fever (≥39℃)

          -  Patients with severe respiratory diseases (ex) bronchial asthma, pneumonia, pulmonary
             tuberculosis, bronchiectasis, mucus sticking, chronic obstructive pulmonary disease
             (COPD), etc.

          -  Patients with a history of hypersensitivity to drug

          -  Patients with abnormal blood coagulation

          -  Patients with thrombocytopenia

          -  Patients with uncontrolled hypertension

          -  Patients with a severe liver disorder(AST or ALT level exceeds 2 times more than
             normal upper range)

          -  Patients woth a clinically significant renal failure(MDRD eGFP &lt; 60 mL/min/1.73m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang-Ha Yoo, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-A Jung, Ph.D</last_name>
    <phone>82-2-410-9038</phone>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang-Ha Yoo, MD, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptokinase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

